Reduce slowness using brain stimulation
- Trial ID
- NCT07397377
- Official Title
- Enhancing rTMS Effects Through a State-Dependent Approach - An Intervention for Bradykinesia in Parkinson's Disease
- Goal
- Reduce slowness using brain stimulation
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Danish Research Centre for Magnetic Resonance
- Study Type
- INTERVENTIONAL
- Enrollment
- 27 participants
- Conditions
- Bradykinesia, Parkinson Disease
- Interventions
- Active patterned repetitive transcranial magnetic stimulation (prTMS), Sham patterned repetitive transcranial magnetic stimulation (prTMS)
Plain-Language Summary
The goal is to reduce bradykinesia, the slowness and reduced movement many people with Parkinson's experience, by boosting the effect of brain stimulation. The approach uses patterned repetitive transcranial magnetic stimulation, noninvasive magnetic pulses delivered to motor brain areas and timed to a person’s brain state to strengthen motor circuits, tested against a sham; it is meant to complement usual Parkinson’s medicines, such as levodopa, not replace them. Adults 18 to 80 with clinically established or probable Parkinson’s who have been on stable antiparkinsonian medication for at least four weeks can apply. People with a personal or close family history of epilepsy, certain psychiatric or GABAergic medications, frequent benzodiazepine or opioid use, pregnancy, or MRI/TMS contraindications are excluded.
Locations
- DRCMR, Hvidovre, Denmark
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Active patterned repetitive transcranial magnetic stimulation (prTMS). The goal is to reduce bradykinesia, the slowness and reduced movement many people with Parkinson's experience, by boosting the effect of brain stimulation. The approach uses patterned repetitive transcranial magnetic stimulation, noninvasive magnetic pulses delivered to motor brain areas and timed to a person’s brain state to strengthen motor circuits, tested against a sham; it is meant to complement usual Parkinson’s medicines, such as levodopa, not replace them. Adults 18 to 80 with clinically established or probable Parkinson’s who have been on stable antiparkinsonian medication for at least four weeks can apply. People with a personal or close family history of epilepsy, certain psychiatric or GABAergic medications, frequent benzodiazepine or opioid use, pregnancy, or MRI/TMS contraindications are excluded.
- Who can participate?
- Participants must be between 18 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 4 months.